Berger & Montague obtained a $52 million
settlement for a class of direct purchasers of the anti-AIDS
medicines Norvir and Kaletra. Norvir serves as a "booster" to
prolong the efficacy of other anti-AIDS drugs.
Berger & Montague, as co-lead counsel, reached the $52
million settlement during trial. Plaintiffs alleged that
defendant Abbott Laboratories quadrupled the price for Norvir,
while selling Kaletra (a combination of the active ingredient in
Norvir and another AIDS drug) below Abbott's cost. These actions
were taken in order to simultaneously increase sales of Kaletra and
to suppress sales of competitors' AIDS treatments which depend on
Norvir as a stand-alone product.